MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

MDT

82.53

-3.2%↓

A

122

+0.95%↑

VEEV

167.85

-0.65%↓

HQY

83.95

-2.51%↓

NEOG

9.42

-2.18%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.63 1.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.52

Max

4.71

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+36.76% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

29M

590M

Eelmine avamishind

2.87

Eelmine sulgemishind

4.63

Uudiste sentiment

By Acuity

50%

50%

159 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. apr 2026, 23:49 UTC

Uudisväärsed sündmused

New Zealand 1Q Inflation Higher Than Expected

20. apr 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20. apr 2026, 22:53 UTC

Suurimad hinnamuutused turgudel

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20. apr 2026, 23:45 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20. apr 2026, 23:44 UTC

Market Talk

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20. apr 2026, 23:39 UTC

Market Talk

Rio Tinto Posts Strong Start to Year -- Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20. apr 2026, 23:09 UTC

Market Talk

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20. apr 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20. apr 2026, 22:26 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Aims for Acquisition to Be Completed by End-2026

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Acquisition Would Be for A$175 Million

20. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20. apr 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20. apr 2026, 21:38 UTC

Market Talk

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20. apr 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20. apr 2026, 21:24 UTC

Market Talk

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20. apr 2026, 21:24 UTC

Market Talk

Global Equities Roundup: Market Talk

20. apr 2026, 21:13 UTC

Tulu

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20. apr 2026, 21:10 UTC

Tulu

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20. apr 2026, 21:09 UTC

Tulu

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20. apr 2026, 21:08 UTC

Tulu

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20. apr 2026, 21:07 UTC

Tulu

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20. apr 2026, 21:05 UTC

Tulu

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20. apr 2026, 21:05 UTC

Tulu

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

36.76% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  36.76%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

159 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat